NOTA-RGDfK acetate | αvβ3 integrin ligand

MedKoo Cat#: 129065 | Name: NOTA-RGDfK acetate

Description:

WARNING: This product is for research use only, not for human or veterinary use.

NOTA-RGDfK is a useful radiolabel ligand peptide that targets αvβ3 integrin, a key marker of angiogenesis overexpressed in various tumors. When labeled with radiometals such as ^68Ga or ^64Cu, NOTA-RGDfK exhibits high binding affinity and specificity to αvβ3 integrin, enabling its use in PET imaging. In preclinical studies, [68Ga]-NOTA-RGDfK demonstrated a dissociation constant (K_d) of ~20–30 nM for αvβ3-positive U87MG glioblastoma cells and showed excellent tumor uptake (e.g., ~2.6–3.5 %ID/g at 1 h post-injection in mouse xenografts), along with rapid blood clearance and low non-target uptake. These properties make NOTA-RGDfK a valuable probe for imaging tumor angiogenesis and monitoring response to anti-angiogenic therapies.

Chemical Structure

NOTA-RGDfK acetate

CAS#N/A

Theoretical Analysis

MedKoo Cat#: 129065

Name: NOTA-RGDfK acetate

CAS#: N/A

Chemical Formula: C41H64N12O14

Exact Mass: 0.0000

Molecular Weight: 949.03

Elemental Analysis: C, 51.89; H, 6.80; N, 17.71; O, 23.60

Price and Availability

Related CAS #

No Data

Synonym

NOTA-RGDfK acetate; NOTA-RGDfK;

IUPAC/Chemical Name

2,2'-(7-(2-((4-((2S,5S,11S,14R)-14-benzyl-11-(carboxymethyl)-5-(3-guanidinopropyl)-3,6,9,12,15-pentaoxo-1,4,7,10,13-pentaazacyclopentadecan-2-yl)butyl)amino)-2-oxoethyl)-1,4,7-triazonane-1,4-diyl)diacetic acid--acetic acid (1/1)

InChi Key

SLZIGDCGMKFWEU-OSEANGNRSA-N

InChi Code

InChI=1S/C39H60N12O12.C2H4O2/c40-39(41)43-12-6-10-26-35(60)44-21-30(52)45-29(20-32(54)55)38(63)48-28(19-25-7-2-1-3-8-25)37(62)47-27(36(61)46-26)9-4-5-11-42-31(53)22-49-13-15-50(23-33(56)57)17-18-51(16-14-49)24-34(58)59;1-2(3)4/h1-3,7-8,26-29H,4-6,9-24H2,(H,42,53)(H,44,60)(H,45,52)(H,46,61)(H,47,62)(H,48,63)(H,54,55)(H,56,57)(H,58,59)(H4,40,41,43);1H3,(H,3,4)/t26-,27-,28+,29-;/m0./s1

SMILES Code

O=C([C@H](CC(O)=O)NC(CNC([C@H](CCCNC(N)=N)NC([C@H](CCCCNC(CN1CCN(CC(O)=O)CCN(CC(O)=O)CC1)=O)N2)=O)=O)=O)N[C@@H](C2=O)CC3=CC=CC=C3.CC(O)=O

Appearance

To be determined

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 -4 C for short term (days to weeks) or -20 C for long term(months to years).

Solubility

To be determined

Shelf Life

>2 years if stored properly

Drug Formulation

To be determined

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Instruction

View handling instruction

Biological target:

In vitro activity:

In vivo activity:

Preparing Stock Solutions

The following data is based on the product molecular weight 949.03 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

Formulation protocol:

In vitro protocol:

In vivo protocol:

Garrow AA, Andrews JPM, Gonzalez ZN, Corral CA, Portal C, Morgan TEF, Walton T, Wilson I, Newby DE, Lucatelli C, Tavares AAS. Preclinical dosimetry models and the prediction of clinical doses of novel positron emission tomography radiotracers. Sci Rep. 2020 Sep 29;10(1):15985. doi: 10.1038/s41598-020-72830-w. PMID: 32994530; PMCID: PMC7525662.